Where Chinese Investors Meet Global Investment News and Opportunities


Fosun and Shanghai Pharmas Competing for $700 Million Stake in US-based Arbor

Shanghai FosunPharma is vying with Shanghai Pharma Holding in a battle to acquire a minority stake in Atlanta’s Arbor Pharma, according to Bloomberg News. Apparently, US private equity company KKR has put its Arbor stake up for sale, with bids expected in the $600-$700 million range. Arbor makes both generic and patented drugs; it also has an active R&D program with seven candidates in clinical trials and another in pre-clinical development. KKR made an investment of undisclosed size in Arbor in late 2014.

Source: ChinaBio Today

Do NOT follow this link or you will be banned from the site!